신생아에서의 항응고요법, 혈전용해요법 및 혈액제제 사용

키워드

참고문헌 (39)

1. Male C, "The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood", Clin Lab Med, 19, pp.39~69 (1999)
2. Thornburg C, "Neonatal thromboembolic emergencies", Semin Fetal Neonatal Med, 11, pp.198~206 (2006)
3. Andrew M, "Heparin therapy in pediatric patients: a prospective cohort study", Pediatr Res, 35, pp.78~83 (1994)
4. Weitz JI, "Low-molecular-weight heparins", N Engl J Med, 337, pp.688~698 (1997)
5. Massicotte P, "Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients", Thromb Res, 109, pp.93~99 (2003)
6. Streif W, "Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients", Arch Dis Child Fetal Neonatal Ed, 88, pp.F365~F370 (2003)
7. Michaels LA, "Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant", Pediatrics, 114, pp.703~707 (2004)
8. Andrew ME, "Thromboembolic disease and antithrombotic therapy in newborns", Hematology Am Soc Hematol Educ Program, pp.358~374 (2001)
9. Streif W, "Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients", Blood, 94, pp.3007~3014 (1999)
10. Rijken DC, "Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells", Thromb Res Suppl, 10, pp.63~71 (1990)
11. Monagle P, "Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", Chest, 126, pp.645S~87S (2004)
12. Manco-Johnson MJ, "Recommendations for tPAthrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis", Thromb Haemost, 88, pp.157~158 (2002)
13. Weiner GM, "Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activator", J Pediatr, 133, pp.133~136 (1998)
14. Zenz W, "Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years", Semin Thromb Hemost, 23, pp.321~332 (1997)
15. Balasa VV, "New anticoagulants: a pediatric perspective", Pediatr Blood Cancer, 45, pp.741~752 (2005)
16. Weitz JI, "New anticoagulants", J Thromb Haemost, 3, pp.1843~1853 (2005)
17. Young G, "Current and future antithrombotic agents in children", Expert Rev Cardiovasc Ther, 2, pp.523~534 (2004)
18. Saxonhouse MA, "The evaluation and management of neonatal coagulation disorders", Semin Perinatol, 33, pp.52~65 (2009)
19. Göbel U, "Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation", Eur J Pediatr, 133, pp.47~49 (1980)
20. Andrew M, "Dysfunctional antithrombin III in sick premature infants", Pediatr Res, 19, pp.237~239 (1985)
21. Nadel S, "Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial", Lancet, 369, pp.836~843 (2007)
22. von Kries R, "Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation", Eur J Pediatr, 144, pp.191~194 (1985)
23. Kreuz WD, "Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency--a feasibility pilot study", Eur J Pediatr, 158(3), pp.S187~S197 (1999)
24. Gross SJ, "Controlled study of treatment for disseminated intravascular coagulation in the neonate", J Pediatr, 100, pp.445~448 (1982)
25. Risch L, "Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes", Intensive Care Med, 30, pp.1615~1624 (2004)
26. Shah PS, "A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study", Pediatrics, 119, pp.e284~e291 (2007)
27. Birch P, "A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial", Arch Dis Child Fetal Neonatal Ed, 95, pp.F252~F257 (2010)
28. Shah PS, "Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters", Cochrane Database Syst Rev, (2), pp.CD002772~ (2008)
29. Shah PS, "Heparin-bonded catheters for prolonging the patency of central venous catheters in children", Cochrane Database Syst Rev, (4), pp.CD005983~ (2007)
30. Barrington KJ, "Umbilical artery catheters in the newborn: effects of heparin", Cochrane Database Syst Rev, (2), pp.CD000507~ (2000)
31. Pal N, "Lakshminarasimhachar A, Avidan MS. Pharmacology and clinical applications of human recombinant antithrombin", Expert Opin Biol Ther, 10, pp.1155~1168 (2010)
32. Warren BL, "Kyber Sept Trial Study Group. Caring for the critically ill patient. Highdose antithrombin III in severe sepsis: a randomized controlled trial", JAMA, 286, pp.1869~1878 (2001)
33. Hoffmann JN, "KyberSept investigators. Benefit", risk profile of highdose antithrombin in patients with severe sepsis treated with and without concomitant heparin, 2006, pp.95, 850~856
34. Hoffmann JN, "Effect of longterm and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis", Crit Care Med, 32, pp.1851~1859 (2004)
35. Mitsiakos G, "Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases", J Pediatr Hematol Oncol, 29, pp.145~150 (2007)
36. Velik-Salchner C, "Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation", Anesth Analg, 101, pp.924~ (2005)
37. Houston G, "Activated protein C for the treatment of severe sepsis", Clin Microbiol Infect, 15, pp.319~324 (2009)
38. Martí-Carvajal A, "Human recombinant activated protein C for severe sepsis", Cochrane Database Syst Rev, (1), pp.CD004388~ (2008)
39. Poterjoy BS, "Platelets, frozen plasma, and cryoprecipitate: what is the clinical evidence for their use in the neonatal intensive care unit", Semin Perinatol, 33, pp.66~74 (2009)

관련 논문AI추천